Bionano Genomics grants 15,000 stock options

Bionano Genomics, Inc. reported that its General Counsel, Jonathan V. Dixon, received a grant of stock options for 15,000 shares of common stock on 2026-08-03.

Rhea-AI Filing Summary

Bionano Genomics, Inc. reported that its General Counsel, Jonathan V. Dixon, received a grant of stock options for 15,000 shares of common stock on 2026-08-03. The options have an exercise price of $1.12 per share and expire on 2036-08-02. The award vests 50% on each of the first and second anniversaries of the vesting commencement date, subject to Continuous Service under the company’s 2018 Plan. Following this grant, Dixon holds options covering 15,000 shares. The company also states that this filing replaces an erroneously filed initial Form 3 dated August 5, 2026.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Dixon Jonathan V.

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	15,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 15,000 contracts (Direct)

Footnotes (2)

1. F1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
2. F2. The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.

Key Figures

Options granted: 15,000 options Exercise price: $1.1200 per share Expiration date: 2036-08-02 +2 more

5 metrics

Options granted 15,000 options Stock option award to General Counsel on 2026-08-03

Exercise price $1.1200 per share Conversion or exercise price for the stock options

Expiration date 2036-08-02 Option expiration for the 15,000-share grant

Post-grant holdings 15,000 options Total options held by Jonathan V. Dixon following this grant

Vesting per anniversary 50% Portion of options vesting on each of first and second anniversaries

Key Terms

Stock Option (Right to Buy), Continuous Service, vesting commencement date, 2018 Plan

4 terms

Stock Option (Right to Buy) financial

"security_title is listed as Stock Option (Right to Buy) for this grant"

Continuous Service financial

"subject to the Reporting Person's Continuous Service through each applicable vesting date"

vesting commencement date financial

"on each of the first and second anniversaries of the vesting commencement date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

2018 Plan financial

"as defined in the Company's 2018 Plan through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Bionano Genomics (BNGO) report for Jonathan V. Dixon?

Bionano Genomics reported that General Counsel Jonathan V. Dixon received a grant of 15,000 stock options. The options relate to common stock, were granted on 2026-08-03, and give him the right to buy shares at a fixed exercise price if vesting conditions are met.

What are the key terms of the 15,000 stock options granted at Bionano Genomics (BNGO)?

The grant covers 15,000 stock options with an exercise price of $1.12 per share and an expiration date of 2036-08-02. These options allow purchase of an equal number of common shares once vested and exercised, subject to plan rules.

How do Jonathan V. Dixon’s BNGO options vest under this award?

The options vest in two equal installments of 50% each. Half vests on the first anniversary and the remaining half on the second anniversary of the vesting commencement date, contingent on his Continuous Service under the company’s 2018 Plan.

How many BNGO options does Jonathan V. Dixon hold after this transaction?

After this reported transaction, Jonathan V. Dixon holds options covering 15,000 shares of Bionano Genomics common stock. This reflects the full amount of the newly granted award, as disclosed in the post-transaction holdings field of the insider report.

Did Bionano Genomics (BNGO) indicate any correction related to prior insider reporting?

Yes. A footnote states that the initial Form 3 filed on August 5, 2026 was erroneously filed. The company explains that this Form 4 replaces that Form 3, clarifying Dixon’s reported derivative holdings through the option grant.

Is the BNGO option grant to Jonathan V. Dixon part of a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative. There is no footnote indicating a pre-arranged trading plan, suggesting this grant is standard equity compensation rather than a transaction executed under a 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 05:28 PM Accepted by SEC EDGAR 08/05/2026 - 05:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dixon Jonathan V.

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.12	08/03/2026		A		15,000		(1)	08/02/2036	Common Stock	15,000	$0	15,000(2)	D

Explanation of Responses:

1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.

2. The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)